Arbutus Plans $230 Million Share Buyback After Moderna Deal
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) plans to return up to approximately $230 million to shareholders after receiving $178.4 million from its patent settlement with Moderna, shifting capital …
Arbutus Plans $230 Million Share Buyback After Moderna Deal Read More